Stryker (SYK) Stock Sinks As Q3 Earnings Cut Full Year View

Stryker just took a hit. The stock dropped 6.5% to US$291.41 today, a sharp reaction to its Q3 2026 earnings release that looks harsher than the underlying report.

The headline is margin power, not collapse. Adjusted earnings per share reached US$3.52 on organic sales growth of 7.7%, with gross and operating margins both moving higher in the quarter. Short-term traders are punishing a reset to full year guidance. Longer horizon investors will likely focus on whether this kind of profitability trend can endure over the next few years.

Like Stryker's margin strength but uneasy about the guidance reset and share price drop today? Compare it with companies that pair pricing power with strong balance sheets in our list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$6,520 million vs. US$6,057 million (up 7.7%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$753 million vs. US$859 million (down 12.3%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$1.97 vs. US$2.25 (down 12.3%)
• Adjusted Operating Margin (Q3 2026 vs. Q3 2025): 26.2% vs. 25.6% (expansion of 60 bps, or 0.6 percentage points)

Earnings tell you how Stryker performed on paper this quarter, but cash flows show what actually hits the corporate bank account and ultimately supports the valuation you see on screen.

When you line up Stryker's cash generation against its current share price, the numbers suggest the stock could be a meaningful 27% undervalued.

Stryker’s Defensive-Growth Story Put To Work

The bullish view hangs on Stryker turning medtech heft into repeatable, sticky business rather than one off wins.

"Stryker is my defensive-growth anchor: a high-quality medtech leader in orthopaedics, surgical equipment and MedSurg, riding the durable tailwind of an ageing population. Demographics, not hype, drive this thesis."

Q3 organic sales of 7.7%, led by MedSurg & Neuro at 9.1%, align with that steady demand idea, even as hips and knees slowed. Margin expansion and roughly US$3.3b of year-to-date operating cash indicate the model continues to generate cash rather than just accounting earnings.

Testing The Risk That Stryker Has No Room For Error

The bear case argues that Stryker’s premium positioning leaves little cushion when execution wobbles.

"Risks include hospital capex cycles, pricing pressure, integration risk from acquisitions, and a premium valuation that leaves little room for execution slips. It is a compounder, not a bargain."

The Q3 revenue and EPS miss, cut to full year EPS guidance, and ongoing peripheral vascular manufacturing issues are the type of slip that tests that concern. Shares dropping 6.5% today after already weaker 90-day returns shows how quickly sentiment can turn when guidance resets and legal scrutiny surfaces.

One Narrative disagrees with today's price. → See where this Narrative says Stryker should trade.

Hunt For Mispriced Earnings Power

Stryker just showed how quickly sentiment can swing when guidance and valuation collide. The real opportunity is finding stocks that could be undervalued before expectations reset.

• Company 1 - 37% below our estimate - targets heavier freight loads while rolling out AI tools to cut fraud and insurance losses.
• Company 2 - 38% below our estimate - rides consumer trade in programs and government backed subsidies to feed a growing device recommerce platform.
• Company 3 - 34% below our estimate - locks in long duration optical and solar contracts that convert customer prepayments into a thicker, higher margin backlog.

Those are three of them. See every one of the 29 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com